Last updated: 12 September 2026 · Content curated by Dr. Shabnam Choudhary · Medically reviewed by Dr. Saffiyyah Chaudhary
Quick Answer
Dendritic Cell Therapy in India is typically planned at $8,000–$22,000. The stored course is Leukapheresis + staged infusions, but the actual timeline depends on cancer type, treatment intent, the named regimen, number of cycles, response, toxicity and whether later cycles continue at home.
The pathway may include leukapheresis, laboratory preparation and staged injections or infusions. Manufacturing method and quality controls must be described. The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests. The medicine, dose and cycle assumptions must appear in the written estimate; a planning range is not a final hospital quotation.
- India cost range
- $8,000–$22,000
- Typical starting point
- $8,000
- Typical hospital stay
- Leukapheresis + staged infusions
- Treatment timeline
- cell collection followed by manufacturing and staged administrations on a programme-specific calendar
- Recovery
- The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests.
Major cost factors: manufacturing protocol, number of administrations, regulatory or trial setting, concurrent standard treatment. International patients should also budget for accommodation, airport transfers, a medical visa, medicines and follow-up.
Often quoted separately: additional pathology, imaging or molecular testing; extra cycles, dose changes or a new regimen; unlisted supportive medicines and blood products; emergency admission or complication care; travel, lodging and care after return.
Why request a cost through GAF rather than a hospital?
Writing to one campus gets you that campus’s package. A GAF request is reviewed against your records and returned as suitable doctor and hospital options with an indicative, itemised estimate. There is no obligation to book.
- Doctor review first. The number follows a reading of your imaging, test results and clinical records, not a brochure range.
- Hospital options. You can compare listed campuses before you travel, instead of starting over with each international desk.
- International-patient coordination. Visa letters, records routing and companion logistics sit with the same request.
Dendritic cell therapy generally refers to an individualised vaccine approach in which antigen-presenting cells are prepared to stimulate an immune response against cancer. Its established role is limited and highly indication-specific; some programmes offer it in selected or investigational settings after standard options and evidence are reviewed.
A medical oncologist should explain the evidence for the exact cancer, product manufacturing, regulatory status, trial context, alternatives and measurable treatment goal before collection. Treatment names are not prescriptions: pathology, stage, organ function, previous therapy, treatment goals and clinical evidence determine what is appropriate.
The pathway may include leukapheresis, laboratory preparation and staged injections or infusions. Manufacturing method and quality controls must be described. The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests.
The catalog stores $8,000–$22,000 for India, $30,000–$80,000 for typical US self-pay and Leukapheresis + staged infusions for travel planning. These are comparison bands, not a drug recommendation, treatment guarantee or final quotation.
What Is Dendritic Cell Therapy?
Dendritic cell therapy generally refers to an individualised vaccine approach in which antigen-presenting cells are prepared to stimulate an immune response against cancer.
The pathway may include leukapheresis, laboratory preparation and staged injections or infusions. Manufacturing method and quality controls must be described.
The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests.
When Is Dendritic Cell Therapy Recommended?
Its established role is limited and highly indication-specific; some programmes offer it in selected or investigational settings after standard options and evidence are reviewed.
It should not replace proven chemotherapy, targeted therapy, immunotherapy, surgery or radiation merely because it is described as personalised or immune boosting.
How treatment is given, monitored and adapted →
Dendritic Cell Therapy cost in India
The $8,000–$22,000 figure is the GAF national planning band for dendritic cell therapy. It may describe consultation, a stated medicine plan, day-care and scheduled monitoring, but it does not establish what one hospital will charge.
Important cost drivers include manufacturing protocol, number of administrations, regulatory or trial setting, concurrent standard treatment, travel and opportunity cost. Medicine acquisition can dominate the invoice, so a quote without drug names, dose and cycle count is not comparable.
No separate Delhi NCR, Mumbai, Bengaluru, Chennai or Hyderabad price is shown unless verified city data exists. This system currently inherits the national band and labels that limitation plainly.
Collection and administration are often outpatient, but a credible programme needs regulated cell processing, clinical oversight and adverse-event reporting. Do not travel on the strength of testimonials. Request protocol, regulatory status, evidence, manufacturing details, total cost and what standard treatment would be delayed.
Dendritic Cell Therapy cost breakdown in India
Component prices are rarely published as a public tariff. The lines below describe what typically sits inside a treatment estimate, not a dollar amount for each row.
- Medical oncologist and pathology review
- Confirmation of diagnosis, stage, intent and whether dendritic cell therapy is supported by the available evidence.
- Biomarker or molecular testing when relevant
- Immunohistochemistry, molecular profiling or germline testing only when clinically indicated. Ask whether tissue review and the test itself are included.
- Named anticancer medicines
- The written regimen, dose basis, brand or biosimilar assumption, vial use and number of cycles. A generic 'drug package' is insufficient.
- Infusion or dispensing
- Collection and administration are often outpatient, but a credible programme needs regulated cell processing, clinical oversight and adverse-event reporting. Confirm day-care nursing, pharmacy preparation and any oral-drug dispensing fees.
- Supportive medicines
- Anti-nausea treatment, hydration, growth-factor support, infection prevention or blood products only when prescribed and explicitly listed.
- Monitoring and follow-up
- The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests. Confirm which blood tests, scans and consultations sit inside the package window.
Planning range or quotation?
The $8,000–$22,000 figure is an indicative planning range. A final hospital quotation is itemised, issued after a consultant reviews your records, and still subject to what is found clinically.
Get a Personalized Cost Estimate
What is usually included in a Dendritic Cell Therapy package?
No two hospitals draw the line in the same place, so read an estimate for what it excludes as carefully as for what it covers. The pattern below is what listed campuses typically bundle into a medical oncology estimate for this treatment. Anything not written into your estimate should be assumed to be extra until the hospital confirms otherwise.
Usually included
Usually included
Named medical-oncology assessment
A consultation tied to the oncologist expected to lead the plan, where bundled.
Usually included
Documented regimen and cycle allowance
The estimate should use the exact treatment name Dendritic Cell Therapy and state medicine, dose basis and number of administrations.
Usually included
Quoted medicine and day-care
Only the brands, biosimilars, vials, pharmacy preparation and infusion visits written into the letter are included.
Usually included
Quoted baseline and on-treatment tests
Blood counts, organ-function tests and response imaging only to the extent listed.
Usually included
Quoted supportive care
Anti-emetics, hydration and other prescribed support only when itemized.
May be charged separately
May be separate
Additional pathology, imaging or molecular testing
Repeat biopsy, outside-slide review, NGS or new imaging may be separate when results are incomplete or the disease has changed.
May be separate
Extra cycles, dose changes or a new regimen
Treatment beyond the stated cycle allowance or a switch after progression or toxicity requires a revised estimate.
May be separate
Unlisted supportive medicines and blood products
Growth factors, antimicrobials, transfusions and symptom-control medicines are not automatically bundled.
May be separate
Emergency admission or complication care
Neutropenic fever, severe immune toxicity, dehydration or organ injury can require inpatient care outside a day-care letter.
May be separate
Travel, lodging and care after return
Flights, visas, companion stay, local transport and monitoring by the home oncology team are normally outside the hospital quote.
Catalog inclusions listed for this pathway: medical oncology consultation and records review; named consultant on camera before travel; protocol, cycles and supportive medicines as quoted; on-treatment reviews and toxicity management; discharge summary to your home oncologist.
What can increase the cost?
These are the drivers that actually move a bill for this procedure, in rough order of how often they do it. Most of them are clinical decisions rather than commercial ones, which is why an honest estimate is written after a records review rather than before it.
- Manufacturing protocol
- Collection, antigen method and laboratory processing define the product.
- Number of administrations
- Staged programmes need a full-course quote.
- Regulatory or trial setting
- Governance and monitoring matter as much as price.
- Concurrent standard treatment
- Chemotherapy or other proven care is usually a separate invoice.
- Travel and opportunity cost
- Time abroad may delay evidence-based care.
Treatment approaches related to Dendritic Cell Therapy
A medical oncologist should explain the evidence for the exact cancer, product manufacturing, regulatory status, trial context, alternatives and measurable treatment goal before collection. The rows below are clinical alternatives or neighbouring pathways, not consumer upgrades.
A medical oncologist should explain why the proposed approach fits the pathology and treatment goal, and what result would trigger a change.
Swipe to compare treatment approaches →
| Approach | Relative complexity | GAF planning range | Notes |
|---|---|---|---|
| Autologous dendritic-cell vaccine | Selected by pathology, stage, biomarkers and treatment intent | No separate GAF sheetRelative complexity only | Patient-derived cells prepared with a defined antigen and manufacturing protocol. |
| Immunotherapy | Selected by pathology, stage, biomarkers and treatment intent | $15,000–$45,000Catalog planning range | A broader, often more established treatment family that should not be conflated with cell vaccines. |
| Clinical-trial participation | Selected by pathology, stage, biomarkers and treatment intent | No separate GAF sheetRelative complexity only | May provide appropriate governance when the approach remains investigational. |
Planning ranges appear only where GAF Healthcare already publishes a cost sheet for that procedure. Other rows describe relative clinical complexity and should not be read as prices.
Side effects and considerations during Dendritic Cell Therapy
Possible effects include injection reactions, fever, fatigue or collection-related issues. Uncertain effectiveness and opportunity cost are also material considerations.
Effects vary by medicine, dose, combination, treatment site, previous therapy and individual health. Not every patient experiences every listed effect, and this is not an exhaustive consent list.
The treating medical oncologist should explain expected effects, urgent warning signs, monitoring and when a dose should be held. No page can promise response, cure or a mild treatment course.
Dendritic Cell Therapy cost: India vs other medical tourism destinations
India and United States values come from the stored GAF registry. Other rows are explicitly modelled from relative private-care levels and are not official drug tariffs or evidence that a medicine is available.
International comparisons fail when the drug, dose, cycle count, biomarker testing and supportive care differ. Obtain like-for-like written estimates after records review.
Swipe to compare destinations →
| Country | Approximate cost | Relative cost position | Important cost considerations |
|---|---|---|---|
| India | $8,000–$22,000 | Baseline | GAF catalog planning range. The stored India figure is a comparison band. A named medical oncologist must review pathology, stage, biomarkers, dose and cycle assumptions before a hospital issues an itemized estimate. |
| Turkey | $16,500–$27,000Indicative planning estimate* | ≈1.4× India | Private international oncology market. Compare the exact medicines, dose basis, number of cycles, laboratory monitoring and supportive drugs rather than a general cancer package. |
| Thailand | $19,500–$33,000Indicative planning estimate* | ≈1.8× India | Private international hospitals. International desks may coordinate care, but medicine acquisition, biomarker testing, day-care fees and lodging between cycles need written confirmation. |
| United Arab Emirates | $33,000–$54,000Indicative planning estimate* | ≈2.9× India | Regional premium private care. Travel may be shorter for Gulf families; pharmacy, infusion, specialist and monitoring charges may still be billed separately. |
| Singapore | $42,000–$72,000Indicative planning estimate* | ≈3.8× India | High-cost specialist private care. Ask for a self-pay estimate tied to drug names, vial use, dose, cycles and biomarker assumptions rather than a broad medical-oncology label. |
| Germany | $37,500–$67,500Indicative planning estimate* | ≈3.5× India | European specialist oncology care. International access, medicine reimbursement, professional billing and follow-up arrangements vary by centre and patient status. |
| United Kingdom | $33,000–$60,000Indicative planning estimate* | ≈3.1× India | Private self-pay for many visitors. Overseas patients should confirm eligibility, private pharmacy pricing, infusion fees and who manages toxicity after they return home. |
| United States | $30,000–$80,000 | ≈3.7× India | Stored self-pay reference. Hospital, oncologist, laboratory, imaging and drug bills may come from different entities. $30,000–$80,000 is a catalog comparison band, not one bundled quotation. |
*Figures other than India and the United States are modelled planning estimates scaled from the India catalog band, not hospital quotations. All figures are planning information. Cancer type, stage, regimen, drug origin, dose, cycles, tests, supportive care, hospital terms and currency can change the final amount; no row predicts outcome.
The point of this table is not that one country is better. Cost level and treatment-market structure are different things. Compare the named hospital, multidisciplinary support, included care and follow-up pathway as carefully as the headline figure.
Which destination is right for you?
Use this only as a reading guide for the table above. It is not a medical recommendation, and it does not rank countries.
Looking for the lowest overall treatment cost?
IndiaLooking for premium private hospital infrastructure?
Singapore / UAELooking for proximity from the Middle East?
UAE / India / TurkeyLooking for established European oncology systems?
Germany / UK
Why do international patients consider India for dendritic cell therapy?
Some international patients consider India for access to medical oncology review, hospital day-care and a self-pay planning band below typical United States figures. Cost alone is not a reason to travel.
The useful comparison is a named oncologist, evidence-based regimen, medicine source, dose and cycle transparency, toxicity cover and a handover that the home team can continue.
No hospital or clinician is described as best. Urgent disease, poor fitness to fly, unstable complications or funded care near home may make international travel inappropriate.
Hospitals for dendritic cell therapy in India
Hospital cards follow exact live treatment and clinician relationships. Accreditation or a general oncology label does not prove current drug availability, molecular-testing access, treatment volume, clinical-trial access or outcomes.
Campuses for this pathway are being confirmed. Ask the desk which houses currently quote it.
Medical oncologists to consider for dendritic cell therapy in India
Profiles are pulled dynamically only when Dendritic Cell Therapy appears in the clinician's current CMS relationships. Verify role, treatment relevance, availability and campus. Placement is not a ranking and this article adds no experience, drug-stock or outcome claim.
Named consultants for this pathway are being matched. Request a dossier and we will advise which campuses can quote it.
Dendritic Cell Therapy cost by city in India
Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad inherit the stored India planning band because no verified city-only tariff is held for these Medical Oncology treatments. A national range is not a local quotation.
Doctor and hospital cards resolve only from exact live CMS relationships. This module names no medicine stock, clinical-trial access, volume, rating or outcome, and an empty card area remains visibly empty.
Swipe to compare Indian cities →
Delhi NCR
$8,000–$22,000
India planning band — not a city quote
Typical stay Leukapheresis + staged infusions
No verified Delhi NCR-only tariff is stored for dendritic cell therapy. Use $8,000–$22,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
0 hospitals · consultant match on request
Mumbai
$8,000–$22,000
India planning band — not a city quote
Typical stay Leukapheresis + staged infusions
No verified Mumbai-only tariff is stored for dendritic cell therapy. Use $8,000–$22,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
0 hospitals · consultant match on request
Bengaluru
$8,000–$22,000
India planning band — not a city quote
Typical stay Leukapheresis + staged infusions
No verified Bengaluru-only tariff is stored for dendritic cell therapy. Use $8,000–$22,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
0 hospitals · consultant match on request
Chennai
$8,000–$22,000
India planning band — not a city quote
Typical stay Leukapheresis + staged infusions
No verified Chennai-only tariff is stored for dendritic cell therapy. Use $8,000–$22,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
0 hospitals · consultant match on request
Hyderabad
$8,000–$22,000
India planning band — not a city quote
Typical stay Leukapheresis + staged infusions
No verified Hyderabad-only tariff is stored for dendritic cell therapy. Use $8,000–$22,000 as the national planning band until a named hospital supplies a regimen-specific quotation.
0 hospitals · consultant match on request
Costs vary considerably by hospital, specialist, clinical complexity, insurance, room or day-care category, and what is included in the package.
Choosing a city for dendritic cell therapy
Patients usually pick the treating team first and the city second. The city still affects daily travel, accommodation, companion arrangements and access to follow-up. Here is what genuinely differs between the five cities we list.
What should international patients budget beyond the treatment medicine?
A complete dendritic cell therapy budget includes more than the $8,000–$22,000 planning band: pathology reconciliation, tests, medicines, infusion or dispensing, supportive care, monitoring, companion travel, lodging and contingency for a delayed or changed cycle.
Travel should follow written clinical acceptance and an itemized estimate. A visa letter or directory card is not medical clearance.
- Records, pathology and prior-treatment review
- Share biopsy, immunohistochemistry, scans, treatment summaries, medicine doses and toxicity history.
- Biomarker review when relevant
- Confirm whether existing tissue is adequate, whether testing could change the plan, and who interprets the result.
- Regimen and itemized estimate
- Match medicine, dose, cycle count, day-care, tests, supportive drugs and emergency exclusions.
- Arrival and baseline assessment
- Allow time for examination, pathology reconciliation and regimen-specific organ-function tests before the first administration.
- Treatment and monitoring
- The pathway may include leukapheresis, laboratory preparation and staged injections or infusions. Manufacturing method and quality controls must be described. The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests.
- Handover and return-home plan
- Travel timing follows collection and administration schedules. Ongoing cancer care and response assessment should remain with a qualified oncology team at home. Carry the treatment summary, doses, toxicity record and next monitoring date.
- Treatment episode$8,000–$22,000
- Pre-operative testsOften inside the estimate — confirm
- Hospital stayLeukapheresis + staged infusions typically bundled
- Additional procedures or extended careQuoted separately if advised
- Accommodation for companionVaries by city and length of stay
- Local transportationAirport and daily hospital transfers
- FlightsDepends on origin
- Medical visaFee set by the issuing consulate
Planning estimate — not a hospital quotation.
Get a Personalized Treatment Estimate
What does medical travel for dendritic cell therapy in India involve?
The sequence below is how a records-first pathway normally runs. The order matters: everything before arrival exists so that you are not making decisions in an unfamiliar hospital corridor with a suitcase beside you.
Send complete oncology records
Provide pathology, immunohistochemistry, imaging files, prior regimens, dose dates, discharge summaries and molecular reports.
Confirm clinical acceptance
A named medical oncologist reviews diagnosis, intent, evidence, travel safety and whether the hospital can source the proposed medicines.
Hold a remote consultation
Ask why this approach is proposed, what alternatives exist, what remains uncertain and who will manage toxicity.
Compare itemized estimates
Use the same medicine, dose and cycle assumptions; do not compare one vial with a whole course.
Plan flexible travel
Obtain required documents and book refundable travel near the exact campus, with contingency for delayed blood counts or extra review.
Repeat necessary baseline checks
The team may reconcile pathology and repeat laboratory, imaging or organ-function tests before treatment.
Receive treatment
The pathway may include leukapheresis, laboratory preparation and staged injections or infusions. Manufacturing method and quality controls must be described. The plan can change for toxicity, response or new pathology information.
Monitor between administrations
The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests.
Review fitness to travel
Travel timing follows collection and administration schedules. Ongoing cancer care and response assessment should remain with a qualified oncology team at home.
Continue care at home
Transfer the regimen, doses, adverse-event record and scan schedule to the local team. Response should be assessed with accepted cancer-specific measures. Standard oncology follow-up must continue regardless of the vaccine programme.
Documents to prepare
- Complete pathology, staging and prior standard-treatment records
- Written protocol and regulatory information from the proposed programme
- Complete pathology report and immunohistochemistry; original slides or blocks if requested
- Recent CT, MRI or PET files rather than phone photographs
- All prior systemic-treatment names, doses, dates and reasons for stopping
- Molecular or germline reports where relevant, including laboratory and specimen details
- Current medicines, allergies, recent blood counts and organ-function tests
Clinical detail
How the treatment is delivered
A medical oncologist should explain the evidence for the exact cancer, product manufacturing, regulatory status, trial context, alternatives and measurable treatment goal before collection.
The pathway may include leukapheresis, laboratory preparation and staged injections or infusions. Manufacturing method and quality controls must be described. Commonly discussed approaches include Autologous dendritic-cell vaccine, Immunotherapy, Clinical-trial participation.
Collection and administration are often outpatient, but a credible programme needs regulated cell processing, clinical oversight and adverse-event reporting. The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests.
Main variations
- Autologous dendritic-cell vaccine
- Patient-derived cells prepared with a defined antigen and manufacturing protocol.
- Immunotherapy
- A broader, often more established treatment family that should not be conflated with cell vaccines.
- Clinical-trial participation
- May provide appropriate governance when the approach remains investigational.
Preparation
A medical oncologist should explain the evidence for the exact cancer, product manufacturing, regulatory status, trial context, alternatives and measurable treatment goal before collection. Send complete reports and imaging files rather than a photograph of a prescription.
Before treatment, the team may repeat blood counts, kidney or liver tests, infection screening, cardiac assessment or pregnancy testing according to the proposed medicine. These are regimen-specific, not universal.
Hospital stay and recovery
Collection and administration are often outpatient, but a credible programme needs regulated cell processing, clinical oversight and adverse-event reporting. Possible effects include injection reactions, fever, fatigue or collection-related issues. Uncertain effectiveness and opportunity cost are also material considerations.
The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests.
The catalog's Leukapheresis + staged infusions is a broad planning guide, not a promise that the patient can fly or stop monitoring on a fixed date.
Response should be assessed with accepted cancer-specific measures. Standard oncology follow-up must continue regardless of the vaccine programme. Seek urgent clinical help for fever, breathing difficulty, new confusion, severe diarrhoea, uncontrolled vomiting, bleeding or any warning sign specified by the treating team.
How to compare Dendritic Cell Therapy quotes from Indian hospitals
Print these and work through them on the video call. A house that answers without hedging is telling you something useful about how it will behave when something goes wrong.
- Why is dendritic cell therapy being considered now, and what alternatives were discussed?
- Has the pathology been reviewed, and is the stage current?
- Is biomarker, molecular or germline testing clinically relevant, and is it included?
- Who is the named medical oncologist, and at which exact campus is treatment delivered?
- Are pathology-review charges included, and are original slides or blocks needed?
- Which medicines, brands or biosimilars are quoted?
- How is the dose calculated, and how many cycles or months are included?
- Are pharmacy preparation, infusion day-care and nursing included?
- Are anti-nausea medicines, hydration and other supportive medicines included?
- Are growth factors or blood products included if prescribed?
- Which blood tests and scans are included?
- What is charged if the dose is held, reduced or changed?
- What happens if additional cycles are recommended?
- Are emergency admission and complication care excluded?
- Are any planned hospital-admission or observation charges included?
- Can later cycles or monitoring continue safely at home?
- Which follow-up consultation and written handover are included?
- What costs are explicitly excluded from the treatment package?
- What is the regulatory status and published evidence for this exact cancer?
- What happens if cell manufacture fails, and which standard treatment must not be delayed?
Frequently asked questions
How much does dendritic cell therapy cost in India?
Dendritic Cell Therapy is typically planned at $8,000–$22,000. This is a stored comparison range, not a quotation; medicine, dose, cycles, testing and hospital terms determine the final amount.
What is dendritic cell therapy?
Dendritic cell therapy generally refers to an individualised vaccine approach in which antigen-presenting cells are prepared to stimulate an immune response against cancer.
When is dendritic cell therapy considered?
Its established role is limited and highly indication-specific; some programmes offer it in selected or investigational settings after standard options and evidence are reviewed.
Does every patient with this cancer need the same treatment?
It should not replace proven chemotherapy, targeted therapy, immunotherapy, surgery or radiation merely because it is described as personalised or immune boosting. Selection requires individual medical-oncology and multidisciplinary review.
Do biomarker or molecular tests affect treatment selection?
A medical oncologist should explain the evidence for the exact cancer, product manufacturing, regulatory status, trial context, alternatives and measurable treatment goal before collection.
How is the treatment given?
The pathway may include leukapheresis, laboratory preparation and staged injections or infusions. Manufacturing method and quality controls must be described.
How long does dendritic cell therapy take?
cell collection followed by manufacturing and staged administrations on a programme-specific calendar. Leukapheresis + staged infusions is the catalog travel-planning assumption, not a fixed course.
Are anticancer medicines included in the hospital package?
Only medicines named in the itemized estimate are included. Confirm the drug, brand or biosimilar, dose, vial use and cycle allowance.
What can make the quotation change?
Important drivers include manufacturing protocol, number of administrations, regulatory or trial setting, concurrent standard treatment, travel and opportunity cost.
What monitoring is usually needed?
The programme should define baseline disease measurement, adverse-event review and a scheduled response assessment rather than relying on nonspecific immune tests.
Can the regimen change after arrival?
Yes. Pathology review, examination, organ function, toxicity or new imaging can change the medicine, dose or timing. The hospital should revise the estimate in writing.
How should an international patient choose a medical oncologist?
Verify the clinician's role, exact procedure relationship, proposed regimen, communication, toxicity cover and handover. Directory placement is not a ranking.
Can later treatment continue after returning home?
Travel timing follows collection and administration schedules. Ongoing cancer care and response assessment should remain with a qualified oncology team at home.
What follow-up is required?
Response should be assessed with accepted cancer-specific measures. Standard oncology follow-up must continue regardless of the vaccine programme.
Dr. Shabnam Choudhary, BDS, is a dental professional who graduated from Al-Ameen Medical College, Bijapur, Karnataka. She contributes to the curation and development of medically informative healthcare content, helping ensure that information is structured clearly and presented in a patient-friendly manner.
Content Curator
Dr. Shabnam Choudhary
BDS
Al-Ameen Medical College, Bijapur, Karnataka
Rajiv Gandhi University of Health Sciences (RGUHS), Bengaluru
Dr. Saffiyyah Chaudhary, BDS, is a dental professional who graduated from Al-Ameen Medical College, Bijapur, Karnataka. She provides medical review of healthcare content to help ensure that clinical information is accurate, understandable, and appropriately presented for patients and their families.
Medically Reviewed By
Dr. Saffiyyah Chaudhary
BDS
Al-Ameen Medical College, Bijapur, Karnataka
Rajiv Gandhi University of Health Sciences (RGUHS), Bengaluru
Related treatment costs
Immunotherapy cost in India
$15,000–$45,000 · stay Outpatient q2–6 weeks
Immune Checkpoint Inhibitor Therapy cost in India
$18,000–$50,000 · stay Outpatient infusions q2–6 weeks
Precision Oncology cost in India
$2,000–$7,000 · stay NGS panel + clinic visit
Cost note
Cost ranges on this page are for preliminary planning and comparison only. The final treatment cost depends on the patient's diagnosis, treatment plan, hospital, doctor, procedure complexity and other clinical factors. A personalized quotation should be obtained before making treatment or travel decisions.
This page is general information about treatment costs and pathways. It is not a diagnosis, a treatment recommendation or a substitute for an individualised medical opinion. Decisions about whether this procedure is appropriate for you belong to a qualified doctor who has reviewed your records.
Last updated 12 September 2026. Cost data is maintained separately from this article and refreshed as listed campuses revise their planning ranges.
Dendritic Cell Therapy cost sheet · All treatment costs in India · Medical Oncology costs
